FRBRX: Franklin Biotechnology Discovery R6

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

FRBRX Franklin Biotechnology Discovery R6

  • Fund
  • FRBRX
  • Price as of: Jan 17, 2020
  • $159.71
    - $0.46 - 0.29%

Profile

FRBRX - Profile

Vitals

  • YTD Return 1.6%
  • 3 Yr Annualized Return 4.6%
  • 5 Yr Annualized Return -2.2%
  • Net Assets $1.2 B
  • Holdings in Top 10 48.6%

52 WEEK LOW AND HIGH

$159.71
$131.46
$169.93

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.70%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 28.62%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $1,000,000
  • IRA N/A

Fund Classification


Distributions

  • YTD Total Return 1.6%
  • 3 Yr Annualized Total Return 5.4%
  • 5 Yr Annualized Total Return 0.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.30%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Franklin Biotechnology Discovery Fund Class R6
  • Fund Family Name
    Franklin Templeton Investments
  • Inception Date
    May 01, 2013
  • Shares Outstanding
    49357
  • Share Class
    Retirement
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Evan McCulloch

Get Updates About FRBRX

Sign up for Advisor Access to receive email updates about FRBRX competitors, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Categories

Performance

FRBRX - Performance

Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD 1.6% 0.0% 6.1% 79.07%
1 Yr 10.1% 2.6% 41.8% 83.19%
3 Yr 4.6%* -9.3% 27.6% 82.57%
5 Yr -2.2%* -9.8% 14.7% 86.79%
10 Yr N/A* -0.8% 18.8% 2.30%

* Annualized

Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2019 24.2% 5.7% 55.4% 23.53%
2018 -18.2% -25.3% 21.5% 88.29%
2017 16.6% -10.8% 43.9% 46.79%
2016 -20.6% -31.6% 6.9% 75.47%
2015 -2.4% -20.4% 13.8% 56.31%

Total Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD 1.6% 0.0% 6.1% 79.07%
1 Yr 10.1% 2.6% 41.8% 83.19%
3 Yr 5.4%* -9.3% 30.8% 83.49%
5 Yr 0.8%* -9.8% 16.7% 76.42%
10 Yr N/A* -0.5% 18.8% 12.64%

* Annualized

Total Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2019 24.2% 5.7% 55.4% 23.53%
2018 -18.2% -25.3% 22.2% 89.19%
2017 19.3% -10.8% 45.8% 52.29%
2016 -16.8% -26.4% 8.7% 70.75%
2015 6.1% -16.6% 15.2% 50.49%

NAV & Total Return History


Holdings

FRBRX - Holdings

Concentration Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Assets 1.2 B 3.58 M 48.1 B 50.39%
Number of Holdings 78 18 399 52.71%
Net Assets in Top 10 575 M 71.5 K 17.4 B 36.43%
Weighting of Top 10 48.55% 21.3% 75.3% 29.46%

Top 10 Holdings

  1. Amgen Inc 8.16%
  2. Vertex Pharmaceuticals Inc 7.06%
  3. Gilead Sciences Inc 5.91%
  4. Biogen Inc 4.79%
  5. Illumina Inc 4.76%
  6. Regeneron Pharmaceuticals Inc 4.15%
  7. Iovance Biotherapeutics Inc 3.65%
  8. Heron Therapeutics Inc 3.57%
  9. Alexion Pharmaceuticals Inc 3.28%
  10. Neurocrine Biosciences Inc 3.22%

Asset Allocation

Weighting Return Low Return High FRBRX % Rank
Stocks
96.92% 48.12% 103.54% 78.29%
Cash
2.88% 0.00% 51.88% 24.81%
Other
0.19% -27.41% 5.17% 34.88%
Preferred Stocks
0.00% 0.00% 1.08% 72.09%
Convertible Bonds
0.00% 0.00% 1.54% 69.77%
Bonds
0.00% 0.00% 20.60% 66.67%

Stock Sector Breakdown

Weighting Return Low Return High FRBRX % Rank
Healthcare
99.92% 58.44% 100.00% 39.53%
Energy
0.08% 0.00% 0.43% 3.10%
Utilities
0.00% 0.00% 0.00% 63.57%
Technology
0.00% 0.00% 16.36% 75.97%
Real Estate
0.00% 0.00% 5.84% 68.22%
Industrials
0.00% 0.00% 2.40% 66.67%
Financial Services
0.00% 0.00% 6.09% 68.22%
Communication Services
0.00% 0.00% 1.02% 65.89%
Consumer Defense
0.00% 0.00% 36.20% 66.67%
Consumer Cyclical
0.00% 0.00% 10.50% 66.67%
Basic Materials
0.00% 0.00% 2.02% 72.09%

Stock Geographic Breakdown

Weighting Return Low Return High FRBRX % Rank
US
88.60% 48.12% 99.93% 26.36%
Non US
8.32% 0.00% 39.36% 79.84%

Expenses

FRBRX - Expenses

Operational Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.70% 0.10% 9.84% 94.49%
Management Fee 0.59% 0.09% 1.30% 19.38%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.15% 0.03% 0.40% 68.09%

Sales Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 28.62% 0.00% 341.00% 21.77%

Distributions

FRBRX - Distributions

Dividend Yield Analysis

FRBRX Category Low Category High FRBRX % Rank
Dividend Yield 0.00% 0.00% 5.20% 68.99%

Dividend Distribution Analysis

FRBRX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Semi-Annually Annually

Net Income Ratio Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Income Ratio -0.30% -2.24% 2.12% 59.84%

Capital Gain Distribution Analysis

FRBRX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

FRBRX - Fund Manager Analysis

Managers

Evan McCulloch


Start Date

Tenure

Tenure Rank

Sep 15, 1997

22.31

22.3%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Steven Kornfeld


Start Date

Tenure

Tenure Rank

Sep 15, 2015

4.3

4.3%

Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.

Wendy Lam


Start Date

Tenure

Tenure Rank

Sep 01, 2018

1.33

1.3%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.59 22.31 9.83 19.68